B Gazzard

Summary

Affiliation: Slotervaart Hospital
Country: The Netherlands

Publications

  1. ncbi Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 727:151-7. 1999
  2. ncbi Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 734:55-61. 1999
  3. ncbi Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 736:123-8. 1999
  4. ncbi The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, 1066 EC Amsterdam, The Netherlands
    J Infect Dis 184:37-42. 2001
  5. ncbi Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
    A I Veldkamp
    Departments of Pharmacy and Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 27:344-9. 2001

Collaborators

  • J M Lange
  • G Moyle
  • M Youle
  • A I Veldkamp
  • R M Hoetelmans
  • J H Beijnen
  • P L Meenhorst
  • J W Mulder
  • R P van Heeswijk
  • M Johnson
  • M O Kwakkelstein
  • M Harris
  • S van der Geest
  • R van Leeuwen
  • J S Montaner
  • H Carlier
  • P Reiss
  • G Schreij
  • R W Sparidans

Detail Information

Publications5

  1. ncbi Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 727:151-7. 1999
    ..This validated assay is suited for use in pharmacokinetic studies with delavirdine and can readily be implemented in the setting of a hospital laboratory for the monitoring of delavirdine concentrations...
  2. ncbi Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 734:55-61. 1999
    ..This validated assay is suited for use in pharmacokinetic studies with efavirenz and can readily be implemented in the setting of a hospital laboratory for the monitoring of efavirenz concentrations...
  3. ncbi Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    J Chromatogr B Biomed Sci Appl 736:123-8. 1999
    ..This validated assay is suited for use in pharmacokinetic studies with abacavir in human plasma and can readily be implemented in the setting of a hospital laboratory for the monitoring of abacavir concentrations...
  4. ncbi The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons
    A I Veldkamp
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, 1066 EC Amsterdam, The Netherlands
    J Infect Dis 184:37-42. 2001
    ..time curve), 36% (minimum plasma concentration), and 17% (maximum plasma concentration). Nevirapine pharmacokinetics appear to be unaffected by coadministration of efavirenz, compared with data from historical control patients...
  5. ncbi Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
    A I Veldkamp
    Departments of Pharmacy and Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 27:344-9. 2001
    ....